INNV-17. Diagnostic Performance and Prognostic Value of the G8 Screening Tool in Older Adults with Newly Diagnosed Glioblastoma, IDH Wild-Type

Abstract Older adults (OA) represent a functionally heterogeneous population. While aging increases vulnerability to disease, not all OA are frail. Cancer, particularly glioblastoma (GBM), is more frequent in OA, with a median age of cancer-related death exceeding 70 years in the U.S. However, they are often underrepresented in clinical trials, leading to challenges in optimizing treatment and patient outcomes. OA with cancer face aging-related biological changes and potentially higher risk for treatment-induced toxicities. The Eastern Cooperative Oncology Group (ECOG) Performance Status Scale and the Karnofsky Performance Status (KPS) score, fail to adequately predict treatment tolerance and functional decline inthis population. The Comprehensive Geriatric Assessment (CGA) evaluates multiple domains including nutrition, mobility, multimorbidity, polypharmacy, geriatric syndromes, cognition, mood, and patient-centered goals. However, CGAs are resource-intensive and require trained personnel. The G8 Geriatric Screening Tool offers a practical alternative—requiring only five minutes to administer without specialized training—while effectively identifying patients who may benefit from a CGA. The G8 tool has demonstrated prognostic value in hematologic malignancies, identifying geriatric impairments and serving as an independent predictor of one-year mortality (hazard ratio 3.93; 95% CI 1.67–9.22, p < 0.001). However, it has not yet been validated in primary brain tumors. This study aims to evaluate the G8’s prognostic value in OA with newly diagnosed GBM and compare its performance with KPS and ECOG scores. The primary objective is to determine whether the G8 screening tool is an independent predictor of 1-year mortality when adjusted for well-known prognostic factors such as age, performance status, extent of resection, and MGMT promoter methylation status. The study population consist of patients ≥70 years (n=100) with newly diagnosed glioblastoma, IDH wild-type from Columbia University Medical Center. Validating the G8 in this population could facilitate improved risk stratification and lay the foundation for a tailored assessment tool for primary brain tumors. NOTE Data is being analized and would be presented at the meeting.